Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page’s revision/version label has been updated from v3.5.2 to v3.5.3, reflecting a site software release rather than a change to the clinical trial record.
    Difference
    0.0%
    Check dated 2026-04-24T05:49:29.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:17:36.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    47 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 is reflected on the page.
    Difference
    0.0%
    Check dated 2026-03-19T04:55:39.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T00:55:21.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed Revision: v3.4.1 along with related funding status notices; these are system-level updates that do not alter study details.
    Difference
    0.4%
    Check dated 2026-02-11T11:37:39.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding status and updated the platform version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:36:53.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.